DRD2 and neoplasm: The anticancer activity of JX57, a derivative of the dopamine receptor D2 antagonist CPZ, could result from its effects on the nervous system and tumor associations; however, in this study, only the direct target of action on tumor cells was assessed, representing a limitation of the study.